Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML

Elihu H. Estey, Peter F. Thall, Xuemei Wang, Srdan Verstovsek, Jorge Cortes, Hagop M. Kantarjian

Research output: Contribution to journalArticle

Abstract

Standardized criteria for complete remission (CR) in acute myeloblastic leukemia (AML) require the absence of peripheral blood blasts (PBBs). However, MD Anderson (MDA) criteria for CR (CR-MDA), although including the other requirements for CR, have not included the PBB count. We exploit this difference to assess the effect of PBBs at the time of CR-MDA on relapse-free survival (RFS) time. Eighty percent of the 533 patients with newly diagnosed AML or refractory anemia with excess of blasts (RAEB) entering CR-MDA from 1995 to 2000 had no PBBs at time of CR-MDA. Ninety-three percent of the remaining patients, who thus had CR-MDA but not standard CR, had 1% to 5% PBBs at this time. Multivariate analyses, using both conventional and Bayesian approaches, indicated that PBBs had no effect on RFS. For all patients and for the subgroups given and not given granulocyte colony-stimulating factor (G-CSF), the 95% credible interval for the relative risk of failure in the PBB group was nearly centered at 1.0. Thus, our data do not support use of PBBs in defining CR in newly diagnosed AML.

Original languageEnglish (US)
Pages (from-to)3097-3099
Number of pages3
JournalBlood
Volume102
Issue number9
DOIs
StatePublished - Nov 1 2003
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Blood
Recurrence
Survival
Refractory Anemia with Excess of Blasts
Bayes Theorem
Granulocyte Colony-Stimulating Factor
Blood Group Antigens
Refractory materials
Multivariate Analysis

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. / Estey, Elihu H.; Thall, Peter F.; Wang, Xuemei; Verstovsek, Srdan; Cortes, Jorge; Kantarjian, Hagop M.

In: Blood, Vol. 102, No. 9, 01.11.2003, p. 3097-3099.

Research output: Contribution to journalArticle

Estey, Elihu H. ; Thall, Peter F. ; Wang, Xuemei ; Verstovsek, Srdan ; Cortes, Jorge ; Kantarjian, Hagop M. / Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. In: Blood. 2003 ; Vol. 102, No. 9. pp. 3097-3099.
@article{b94b7c6c06f74f5bad61c51fe8a5f09b,
title = "Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML",
abstract = "Standardized criteria for complete remission (CR) in acute myeloblastic leukemia (AML) require the absence of peripheral blood blasts (PBBs). However, MD Anderson (MDA) criteria for CR (CR-MDA), although including the other requirements for CR, have not included the PBB count. We exploit this difference to assess the effect of PBBs at the time of CR-MDA on relapse-free survival (RFS) time. Eighty percent of the 533 patients with newly diagnosed AML or refractory anemia with excess of blasts (RAEB) entering CR-MDA from 1995 to 2000 had no PBBs at time of CR-MDA. Ninety-three percent of the remaining patients, who thus had CR-MDA but not standard CR, had 1{\%} to 5{\%} PBBs at this time. Multivariate analyses, using both conventional and Bayesian approaches, indicated that PBBs had no effect on RFS. For all patients and for the subgroups given and not given granulocyte colony-stimulating factor (G-CSF), the 95{\%} credible interval for the relative risk of failure in the PBB group was nearly centered at 1.0. Thus, our data do not support use of PBBs in defining CR in newly diagnosed AML.",
author = "Estey, {Elihu H.} and Thall, {Peter F.} and Xuemei Wang and Srdan Verstovsek and Jorge Cortes and Kantarjian, {Hagop M.}",
year = "2003",
month = "11",
day = "1",
doi = "10.1182/blood-2003-04-1309",
language = "English (US)",
volume = "102",
pages = "3097--3099",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML

AU - Estey, Elihu H.

AU - Thall, Peter F.

AU - Wang, Xuemei

AU - Verstovsek, Srdan

AU - Cortes, Jorge

AU - Kantarjian, Hagop M.

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Standardized criteria for complete remission (CR) in acute myeloblastic leukemia (AML) require the absence of peripheral blood blasts (PBBs). However, MD Anderson (MDA) criteria for CR (CR-MDA), although including the other requirements for CR, have not included the PBB count. We exploit this difference to assess the effect of PBBs at the time of CR-MDA on relapse-free survival (RFS) time. Eighty percent of the 533 patients with newly diagnosed AML or refractory anemia with excess of blasts (RAEB) entering CR-MDA from 1995 to 2000 had no PBBs at time of CR-MDA. Ninety-three percent of the remaining patients, who thus had CR-MDA but not standard CR, had 1% to 5% PBBs at this time. Multivariate analyses, using both conventional and Bayesian approaches, indicated that PBBs had no effect on RFS. For all patients and for the subgroups given and not given granulocyte colony-stimulating factor (G-CSF), the 95% credible interval for the relative risk of failure in the PBB group was nearly centered at 1.0. Thus, our data do not support use of PBBs in defining CR in newly diagnosed AML.

AB - Standardized criteria for complete remission (CR) in acute myeloblastic leukemia (AML) require the absence of peripheral blood blasts (PBBs). However, MD Anderson (MDA) criteria for CR (CR-MDA), although including the other requirements for CR, have not included the PBB count. We exploit this difference to assess the effect of PBBs at the time of CR-MDA on relapse-free survival (RFS) time. Eighty percent of the 533 patients with newly diagnosed AML or refractory anemia with excess of blasts (RAEB) entering CR-MDA from 1995 to 2000 had no PBBs at time of CR-MDA. Ninety-three percent of the remaining patients, who thus had CR-MDA but not standard CR, had 1% to 5% PBBs at this time. Multivariate analyses, using both conventional and Bayesian approaches, indicated that PBBs had no effect on RFS. For all patients and for the subgroups given and not given granulocyte colony-stimulating factor (G-CSF), the 95% credible interval for the relative risk of failure in the PBB group was nearly centered at 1.0. Thus, our data do not support use of PBBs in defining CR in newly diagnosed AML.

UR - http://www.scopus.com/inward/record.url?scp=0142214653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142214653&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-04-1309

DO - 10.1182/blood-2003-04-1309

M3 - Article

C2 - 12842982

AN - SCOPUS:0142214653

VL - 102

SP - 3097

EP - 3099

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -